Prøve GULL - Gratis

Bio Spectrum - February 2020

filled-star
Bio Spectrum

Gå ubegrenset med Magzter GOLD

Lese Bio Spectrum sammen med 9000+ andre magasiner og aviser med bare ett abonnement  

Se katalog

1 måned

$14.99

1 år

$149.99

$12/month

(OR)

Abonner kun på Bio Spectrum

Kjøp denne utgaven: February 2020

1 problemer som starter fra February 2020

12 problemer som starter fra February 2020

Kjøp denne utgaven

$0.99

1 år

$10.99

Please choose your subscription plan

Avbryt når som helst.

(Ingen forpliktelser) ⓘ

Hvis du ikke er fornøyd med abonnementet, kan du sende oss en e-post på help@magzter.com innen 7 dager etter abonnementets startdato for full refusjon. Ingen spørsmål - lover! (Merk: Gjelder ikke for enkeltutgavekjøp)

Digitalt abonnement

Øyeblikkelig tilgang ⓘ

Abonner nå for å begynne å lese umiddelbart på Magzter-nettstedet, iOS, Android og Amazon-appene.

Verifisert sikker

betaling ⓘ

Magzter er en verifisert Authorize.Net-forhandler. Les mer

I dette nummeret

Indian pharma under USFDA lens

India holds a major stake in the US market. Hence US Food Drug Administration (FDA) has imposed stringent regulations to meet the international regulatory requirement which further boosts number of inspections carried out at various facilities on Indian pharmaceutical companies. With the booming generics business, USFDA is keeping a stern watch over the Indian pharma companies to safeguard the health interest of its population. The government of India has been adopting to stringent mechanisms to ensure the quality of drugs into the market. The Ministry of Health has been imposing a mandatory BA/BE studies for all the pharmaceutical manufacturing permissions. Government’s “Make in India” initiative is expected to deliver more safe, efficient and quality drugs into the market. With these and many more initiatives India will continue to be the powerhouse of pharmaceutical industry in coming years.

Bio Spectrum Description:

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

Nylige utgaver

Spesielle problemer

  • March 2013

    March 2013

Relaterte titler

Populære kategorier